Home
/
INTEGRATED BIOPHARMA INC
/
Financials
/
Quarterly
INTEGRATED BIOPHARMA INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that INTEGRATED BIOPHARMA INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2019
Sep 30, 2018
$10.30M
Nov 9, 2018
Q3
2018
Mar 31, 2018
$10.58M
May 9, 2018
Q1
2019
Sep 30, 2017
$9.77M
Nov 9, 2018
Q3
2018
Mar 31, 2017
$10.65M
May 9, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Dec 31, 2017
$10.80M
Feb 9, 2018
Q1
2018
Sep 30, 2017
$9.77M
Nov 9, 2017
Q3
2017
Mar 31, 2017
$10.65M
May 10, 2017
Q2
2018
Dec 31, 2016
$12.37M
Feb 9, 2018
Q1
2018
Sep 30, 2016
$12.68M
Nov 9, 2017
Q3
2017
Mar 31, 2016
$10.97M
May 10, 2017
Q2
2017
Dec 31, 2015
$10.41M
Feb 10, 2017
Q1
2017
Sep 30, 2015
$9.45M
Nov 10, 2016
Q3
2016
Mar 31, 2015
$9.67M
May 13, 2016
Q2
2016
Dec 31, 2014
$10.29M
Feb 19, 2016
Q1
2016
Sep 30, 2014
$8.58M
Nov 5, 2015
Q3
2015
Mar 31, 2014
$7.52M
May 14, 2015
Q2
2015
Dec 31, 2013
$8.79M
Feb 17, 2015
Q1
2014
Sep 30, 2013
$9.19M
Nov 14, 2013
Q1
2014
Sep 30, 2012
$8.48M
Nov 14, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
($762.0K)
Feb 11, 2026
Q2
2026
Sep 30, 2025
$123.0K
Feb 11, 2026
Q1
2026
Sep 30, 2025
$123.0K
Nov 10, 2025
Q3
2025
Mar 31, 2025
$611.0K
May 14, 2025
Q2
2026
Dec 31, 2024
$116.0K
Feb 11, 2026
Q3
2025
Dec 31, 2024
$116.0K
May 14, 2025
Q1
2026
Sep 30, 2024
$259.0K
Nov 10, 2025
Q2
2026
Sep 30, 2024
$259.0K
Feb 11, 2026
Q3
2025
Sep 30, 2024
$259.0K
May 14, 2025
Q3
2025
Mar 31, 2024
$285.0K
May 14, 2025
Q2
2025
Dec 31, 2023
($382.0K)
Feb 13, 2025
Q3
2025
Dec 31, 2023
($382.0K)
May 14, 2025
Q3
2025
Sep 30, 2023
($59.0K)
May 14, 2025
Q1
2025
Sep 30, 2023
($59.0K)
Nov 13, 2024
Q2
2025
Sep 30, 2023
($59.0K)
Feb 13, 2025
Q3
2024
Mar 31, 2023
$16.0K
May 10, 2024
Q2
2024
Dec 31, 2022
($55.0K)
Feb 12, 2024
Q3
2024
Dec 31, 2022
($55.0K)
May 10, 2024
Q3
2024
Sep 30, 2022
($35.0K)
May 10, 2024
Q2
2024
Sep 30, 2022
($35.0K)
Feb 12, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
($914.0K)
Feb 11, 2026
Q1
2026
Sep 30, 2025
$163.0K
Nov 10, 2025
Q3
2025
Mar 31, 2025
$739.0K
May 14, 2025
Q2
2026
Dec 31, 2024
$202.0K
Feb 11, 2026
Q1
2026
Sep 30, 2024
$490.0K
Nov 10, 2025
Q3
2025
Mar 31, 2024
$355.0K
May 14, 2025
Q2
2025
Dec 31, 2023
($452.0K)
Feb 13, 2025
Q1
2025
Sep 30, 2023
($54.0K)
Nov 13, 2024
Q3
2024
Mar 31, 2023
$44.0K
May 10, 2024
Q2
2024
Dec 31, 2022
($33.0K)
Feb 12, 2024
Q1
2024
Sep 30, 2022
$30.0K
Nov 9, 2023
Q3
2023
Mar 31, 2022
$992.0K
May 11, 2023
Q2
2023
Dec 31, 2021
$730.0K
Feb 10, 2023
Q1
2023
Sep 30, 2021
$585.0K
Nov 10, 2022
Q3
2022
Mar 31, 2021
$1.72M
May 12, 2022
Q2
2022
Dec 31, 2020
$1.24M
Feb 10, 2022
Q1
2021
Sep 30, 2020
$1.51M
Nov 10, 2021
Q3
2021
Mar 31, 2020
$960.0K
May 13, 2021
Q2
2021
Dec 31, 2019
$1.21M
Feb 12, 2021
Q1
2021
Sep 30, 2019
$476.0K
Nov 12, 2020